中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

165 records (took 0.054 seconds)

    AUTOSOMAL-IDENTICAL PLURIPOTENT STEM CELL POPULATIONS HAVING NON-IDENTICAL SEX CHROMOSOMAL COMPOSITION AND USES THEREOF
    81.
    发明申请
    AUTOSOMAL-IDENTICAL PLURIPOTENT STEM CELL POPULATIONS HAVING NON-IDENTICAL SEX CHROMOSOMAL COMPOSITION AND USES THEREOF 审中-公开
    具有非同源性染色体组成的自发相同多能干细胞种群及其用途

    公开(公告)号：WO2017130205A1

    公开(公告)日：2017-08-03

    申请号：PCT/IL2017/050111

    申请日：2017-01-31

    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

    Inventor： WALDHORN, Ithai ,  REUBINOFF, Benjamin Eithan

    IPC: C12N5/074

    CPC classification number: C12N5/0696

    Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non- identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.

    Abstract translation: 公开了一种制造物品，其包含至少两个常染色体相同的诱导性多能干细胞（iPSC）群体，其中所述至少两个群体的第一群体的性染色体的补体是非 - 与至少两个群体的第二群体的性染色体的补体相同。 本发明还公开了其用途及其生成方法。

    METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING UROTHELIAL CANCER
    83.
    发明申请
    METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING UROTHELIAL CANCER 审中-公开
    用于诊断和治疗尿路癌的方法和组合物

    公开(公告)号：WO2016203476A1

    公开(公告)日：2016-12-22

    申请号：PCT/IL2016/050637

    申请日：2016-06-16

    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ,  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

    Inventor： HOCHBERG, Avraham ,  GOFRIT, Ofer N. ,  STERNBERG, Itay Aharon

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/158

    Abstract: A method of diagnosing urothelial cancer in a subject is provided. The method comprising: (a) determining a presence and/or a level of an expression product of a H19 gene in a biological fluid sample of the subject, wherein the presence and/or the level of the expression product of the H19 gene above a predetermined threshold is indicative of presence of a cell of the urothelial cancer; and (b) wherein when an absence and/or a level of the expression product of the H19 gene below a predetermined threshold is indicated classifying the subject as free of the urothelial cancer without subjecting the subject to cystoscopy; and wherein when the presence and/or the level of the expression product of the H19 gene above a predetermined threshold is indicated corroborating presence of a cell of the urothelial cancer using the cystoscopy.

    Abstract translation: 提供了一种在受试者中诊断尿路上皮癌的方法。 该方法包括：（a）确定受试者的生物流体样品中H19基因的表达产物的存在和/或水平，其中H19基因的表达产物的存在和/或水平高于 预定阈值表示尿路上皮癌细胞的存在; 和（b）其中当H19基因的表达产物的不存在和/或水平低于预定阈值时，表明将受试者分类为没有尿路上皮癌，而不对受试者进行膀胱镜检查; 并且其中当所述H19基因的表达产物的存在和/或水平高于预定阈值时，使用膀胱镜检查来证实存在尿路上皮癌的细胞。

    MARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS AND PREDICTING RESPONSIVENESS TO INTERFERON TREATMENT
    85.
    发明申请
    MARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS AND PREDICTING RESPONSIVENESS TO INTERFERON TREATMENT 审中-公开
    诊断多发性硬化症和预防干扰素治疗反应的标记

    公开(公告)号：WO2015140793A1

    公开(公告)日：2015-09-24

    申请号：PCT/IL2015/050278

    申请日：2015-03-16

    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

    Inventor： LAVON, Iris ,  VAKNIN, Adi

    IPC: C12Q1/68 ,  G01N33/68 ,  A61P25/00

    CPC classification number: C12Q1/68 ,  C12Q1/6883 ,  C12Q2600/106 ,  G01N33/564 ,  G01N2800/285 ,  G01N2800/52

    Abstract: The present invention provides methods for diagnosing multiple sclerosis (MS) and prediction of responsiveness to interferon treatment. In specific embodiments, the present invention provides a gene expression profile for the prediction of responsiveness to interferon, (e.g., IFNβ) treatment of subjects having multiple sclerosis. The present invention further provides a method of treating a subject in need of IFN treatment comprising predicting the responsiveness of the subject to IFN treatment and selecting a treatment regimen based on said prediction.

    Abstract translation: 本发明提供诊断多发性硬化症（MS）和预测对干扰素治疗的反应性的方法。 在具体实施方案中，本发明提供用于预测对具有多发性硬化症的受试者的干扰素（例如，IFNβ）的反应性的基因表达谱。 本发明还提供了治疗需要IFN治疗的受试者的方法，包括预测受试者对IFN治疗的反应性并基于所述预测选择治疗方案。

    ALGINATE COMPOSITIONS AND USES THEREOF
    88.
    发明申请
    ALGINATE COMPOSITIONS AND USES THEREOF 审中-公开
    ALGINATE组合物及其用途

    公开(公告)号：WO2014102802A1

    公开(公告)日：2014-07-03

    申请号：PCT/IL2013/051089

    申请日：2013-12-30

    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ,  B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD.

    Inventor： COHEN, Smadar ,  ILAN, Yaron ,  SHTEYER, Eyal ,  BEN-YA'ACOV, Ami

    IPC: A61K31/734 ,  A61P1/16 ,  A61P29/00

    CPC classification number: A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

    Abstract: Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than -25 mV, at a concentration of 0.5 % (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10 -8 cm 2 /millisecond, at a concentration of 0.5 % (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease, liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.

    Abstract translation: 包含藻酸盐，钠离子源和载体（例如药学上可接受的载体）的组合物，其特征在于藻酸盐链的缔合减少，因此通过以下至少一种：（i）弱于-25的ζ电位 mV，载体中浓度为0.5％（w / v）藻酸盐; 和（ii）载体中浓度为0.5％（w / v）藻酸盐的至少10-8cm 2 /毫秒的扩散系数。 还公开了利用组合物治疗炎症性肠病，肝损伤，疾病和病症的组合物和方法的用途，用于治疗由肝毒性剂治疗的医学病症，以及用于减少或预防肝损伤，包括由肝毒性引起的肝损伤 剂。

Patent Agency Ranking